| payload |
{"created_at":"2026-04-21T12:20:48.730 {"created_at":"2026-04-21T12:20:48.730501+00:00","dedupe_key":"signal_enriched:discovery_unusual_volume_delta:df0429fb66ec9585","evidence_event_ids":["evt_c3321a031c39"],"signal_type":"discovery_unusual_volume_delta","source":"discovery_ingestor","value":{"aggregator_url":"https://www.nasdaq.com/articles/quest-diagnostics-raises-2026-eps-revenue-guidance","as_of":"2026-04-21T12:20:48.730501+00:00","canonical_url":"https://www.rttnews.com/3640695/quest-diagnostics-raises-2026-eps-revenue-guidance.aspx","enrichment":{"aggregator_url":"https://www.nasdaq.com/articles/quest-diagnostics-raises-2026-eps-revenue-guidance","article_chars":953,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_2023192d09610e6a","canonical_host":"rttnews.com","canonical_is_aggregator":false,"canonical_url":"https://www.rttnews.com/3640695/quest-diagnostics-raises-2026-eps-revenue-guidance.aspx","content_type":"text/html; charset=utf-8","enriched_at":"2026-04-21T22:34:52.301353+00:00","extraction_method":"trafilatura","fetched_description":"(RTTNews) - Quest Diagnostics (DGX) said, for full year 2026, the company now expects adjusted diluted EPS in a range of $10.63 $10.83, revised from prior guidance range of $10.50 $10.70. Net revenues are now expected in a range of $11.78 billion to $11.90 billion, updated from p","fetched_title":"Quest Diagnostics Raises 2026 EPS, Revenue Guidance | Nasdaq","final_url":"https://www.nasdaq.com/articles/quest-diagnostics-raises-2026-eps-revenue-guidance","html_truncated":false,"paywall_likely":false,"publisher_domain":"rttnews.com","publisher_resolution":"canonical_url","requested_url":"https://www.nasdaq.com/articles/quest-diagnostics-raises-2026-eps-revenue-guidance","source_event_id":"evt_c3321a031c39","source_quality":"medium","status_code":200,"version":"signal_enrichment_v2"},"fp":"9aaa27fb59466f72","kind":"unusual_volume","published_at":"2026-04-21T11:21:37+00:00","publisher_domain":"rttnews.com","signal_understanding":{"analysis_basis":"article","claim_confidence":0.78,"dates_mentioned":["2026","first quarter","last year"],"entities":[{"asset_class":"equity","name":"Quest Diagnostics","relevance":"high","symbol":"DGX","type":"company"},{"asset_class":"other","name":"NYSE","relevance":"medium","symbol":"","type":"exchange"}],"event_type":"earnings","information_gaps":["The signal type is 'discovery_unusual_volume_delta', but the provided text contains no volume ratio, baseline volume, or direction for unusual trading volume.","No explicit statement confirms whether any volume change is news-driven or unexplained.","No catalyst hypothesis for unusual volume is provided in the text; only guidance revision and Q1 results are described."],"key_facts":["Full-year 2026 adjusted diluted EPS guidance revised to $10.63\u2013$10.83 from prior $10.50\u2013$10.70.","Full-year 2026 net revenue guidance revised to $11.78B\u2013$11.90B from prior $11.70B\u2013$11.82B.","First quarter bottom line totaled $252 million, or $2.24 per share, versus $220 million, or $1.94 per share last year.","First quarter adjusted earnings (excluding items) were $281 million, or $2.50 per share.","First quarter revenue rose 9.1% to $2.89 billion from $2.65 billion.","In pre-market trading on NYSE, Quest shares were up 2.39% to $201.00."],"numeric_claims":[{"label":"2026 adjusted diluted EPS (range, $)","value":"10.63\u201310.83"},{"label":"Prior 2026 adjusted diluted EPS (range, $)","value":"10.50\u201310.70"},{"label":"2026 net revenue (range, $B)","value":"11.78\u201311.90"},{"label":"Prior 2026 net revenue (range, $B)","value":"11.70\u201311.82"},{"label":"Q1 bottom line (million $)","value":"252"},{"label":"Q1 EPS (bottom line, $)","value":"2.24"},{"label":"Q1 prior-year bottom line (million $)","value":"220"},{"label":"Q1 prior-year EPS (bottom line, $)","value":"1.94"},{"label":"Q1 adjusted earnings (million $)","value":"281"},{"label":"Q1 adjusted EPS (excluding items, $)","value":"2.50"},{"label":"Q1 revenue (billion $)","value":"2.89"},{"label":"Q1 prior-year revenue (billion $)","value":"2.65"},{"label":"Q1 revenue growth (%)","value":"9.1"},{"label":"Pre-market price move (%)","value":"2.39"},{"label":"Pre-market price ($)","value":"201.00"}],"primary_claim":"Quest Diagnostics raised its 2026 adjusted diluted EPS guidance to $10.63\u2013$10.83 and net revenue guidance to $11.78B\u2013$11.90B.","relevance_score":0.62,"sentiment":"positive","source_quality":"medium","summary":"Quest Diagnostics (DGX) raised its full-year 2026 adjusted diluted EPS and net revenue guidance, and reported stronger Q1 results. The signal does not provide any unusual trading volume metrics.","topics":["earnings guidance","EPS guidance","revenue guidance","Quest Diagnostics","DGX stock move"]},"source":"Nasdaq Markets","source_domain":"rttnews.com","summary":"(RTTNews) - Quest Diagnostics (DGX) said, for full year 2026, the company now expects adjusted diluted EPS in a range of $10.63 $10.83, revised from prior guidance range of $10.50 $10.70. Net revenues are now expected in a range of $11.78 billion to $11.90 billion, updated from p","tickers":["DGX"],"title":"Quest Diagnostics Raises 2026 EPS, Revenue Guidance","url":"https://www.rttnews.com/3640695/quest-diagnostics-raises-2026-eps-revenue-guidance.aspx"}}... |